Rezvilutamide for metastatic hormone-sensitive prostate cancer - Authors' reply

Lancet Oncol. 2022 Nov;23(11):e491. doi: 10.1016/S1470-2045(22)00630-1.

¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China. Electronic address: dwyeli@163.com.
² Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China.
³ Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.

No abstract available

Publication types